ICML 2019 | ROBUST study: why did it not meet its primary endpoint? A subgroup analysis

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Umberto Vitolo from City of Health and Science University Hospital, Turin, IT, about the ROBUST study and what factors could be attributed to the study failing its primary endpoint.

Umberto Vitolo discusses the ROBUST trial, which was presented for the first time at ICML 2019. The international, phase III, randomized study showed that lenalidomide can act in various ways in different subgroups, with Umberto mentioning that further results are expected next year.